CAMP4 Therapeutics Corporation (CAMP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-1164.1%

-$40.17

vs $3.78 price

Levered DCF

-$107.03

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-5.32

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023
P/E	-2.31×	-1.96×	-2.63×
P/B	3.9×	1.61×	-1.05×
P/S	53.24×	156.16×	371.36×
EV / EBITDA	-1.56×	-0.9×	-2.06×
Gross margin	53.1%	100.0%	100.0%
Operating margin	-1488.3%	-8142.3%	-14822.6%
Net margin	-2298.5%	-7943.4%	-14083.1%
Current ratio	7.35×	6.92×	5.13×
Debt / equity	0.04×	0.14×	-0.09×
Interest coverage	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023
Return on equity	-168.5%	-82.0%	39.8%
Return on invested capital	-50.8%	-73.9%	-103.4%
Return on assets	-68.2%	-66.1%	-89.7%
Free cash flow yield	-16.0%	-45.2%	-34.5%
Earnings yield	-43.2%	-50.9%	-37.9%
Enterprise value	$78.7M	$46.4M	$103.3M
Net debt / EBITDA	2.13×	1.08×	0.53×
Cash conversion cycle (days)	-24	60	461